153 related articles for article (PubMed ID: 1388699)
1. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.
Checkoway H; Costa LG; Woods JS; Castoldi AF; Lund BO; Swanson PD
J Neural Transm Park Dis Dement Sect; 1992; 4():283-90. PubMed ID: 1388699
[TBL] [Abstract][Full Text] [Related]
2. Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease.
Kushleika J; Checkoway H; Woods JS; Moon JD; Smith-Weller T; Franklin GM; Swanson PD
Ann Neurol; 1996 Mar; 39(3):378-81. PubMed ID: 8602757
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
4. Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Husain M; Shukla R; Dikshit M; Maheshwari PK; Nag D; Srimal RC; Seth PK; Khanna VK
Neurochem Res; 2009 Aug; 34(8):1427-32. PubMed ID: 19259810
[TBL] [Abstract][Full Text] [Related]
5. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
[TBL] [Abstract][Full Text] [Related]
7. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
Sandler M
J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
[TBL] [Abstract][Full Text] [Related]
8. Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls.
Finch CC; Ho SL; Williams AC; Billett EE
Prog Brain Res; 1995; 106():85-90. PubMed ID: 8584677
[No Abstract] [Full Text] [Related]
9. Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
Kuhn W; Müller T; Gerstner A; Winkel R; Goetz ME
Can J Neurol Sci; 1998 Aug; 25(3):249-51. PubMed ID: 9706728
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
11. A review of the pharmacology of selegiline.
Heinonen EH; Lammintausta R
Acta Neurol Scand Suppl; 1991; 136():44-59. PubMed ID: 1686954
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
13. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
Zhou G; Miura Y; Shoji H; Yamada S; Matsuishi T
J Neurol Neurosurg Psychiatry; 2001 Feb; 70(2):229-31. PubMed ID: 11160474
[TBL] [Abstract][Full Text] [Related]
14. Is selegiline neuroprotective in Parkinson's disease?
Gerlach M; Youdim MB; Riederer P
J Neural Transm Suppl; 1994; 41():177-88. PubMed ID: 7931225
[TBL] [Abstract][Full Text] [Related]
15. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
16. Superoxide dismutase activity in early and advanced Parkinson's disease.
Bostantjopoulou S; Kyriazis G; Katsarou Z; Kiosseoglou G; Kazis A; Mentenopoulos G
Funct Neurol; 1997; 12(2):63-8. PubMed ID: 9238339
[TBL] [Abstract][Full Text] [Related]
17. Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Kuiper MA; Konings CH; Bergmans PL; Wolters EC
J Neurol Sci; 1993 Jul; 117(1-2):41-5. PubMed ID: 8410065
[TBL] [Abstract][Full Text] [Related]
18. Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
van Kempen GM; Janjua R; Roos RA
Clin Neurol Neurosurg; 1995 May; 97(2):131-3. PubMed ID: 7656485
[TBL] [Abstract][Full Text] [Related]
19. Platelet monoamine oxidase B activity in parkinsonian patients.
Bonuccelli U; Piccini P; Del Dotto P; Pacifici GM; Corsini GU; Muratorio A
J Neurol Neurosurg Psychiatry; 1990 Oct; 53(10):854-5. PubMed ID: 2266365
[TBL] [Abstract][Full Text] [Related]
20. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Götz ME; Gerstner A; Harth R; Dirr A; Janetzky B; Kuhn W; Riederer P; Gerlach M
J Neural Transm (Vienna); 2000; 107(1):41-8. PubMed ID: 10809402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
